Laminin-332 pemphigoid, a subset of mucous membrane pemphigoid (MMP), is a rare and chronic, autoimmune blistering disease which results in subepidermal blisters and erosive lesions predominantly localized to mucous membranes. 1 The pathogenesis involves IgG autoantibodies against laminin-332 in the basement membrane zone (BMZ). 1 While typically clinically indistinguishable from other forms of mucous membrane pemphigoid, laminin-332 pemphigoid appears to predispose to more aggressive laryngopharyngeal involvement. [2][3][4][5] Complications from laminin-332 include scarring, which can lead to blindness or strictures along the oral-gastrointestinal and urogenital and tracts. 3,4 Laminin-332 is an extracellular glycoprotein and a vital component of the BMZ. It is a heterotrimer composed of the domains α3, β3 and γ2 with a large G domain at the base containing epidermal growth factor-based repeats. 6,7 While laminin α3 is the most frequently targeted domain in laminin-332 pemphigoid, patients often express varying amounts of β3 and γ2 antibodies. 5,8 The unique cross-shaped structure of laminin-332 and its various C-terminal